Indacaterol maleate for the treatment of chronic obstructive pulmonary disease

Bibliography

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated Dec 2009). Available from: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003 [Last accessed June, 2010]
   Google Scholar
• Calverley PM, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, A four-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
   PubMed Web of Science ®Google Scholar
• Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta-agonist for the treatment of obstructive airways diseases. Adv Ther 2009;26:691-9
   PubMedGoogle Scholar
• Battram C, Charlton SJ, Cuenoud B, In vitro and in vivo pharmacological characterization of 5-[R-2-(5,6-diethyl-indan-2-ylamino)-1-dhyroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a novel inhaled beta2 adrenoceptor agaonist with a 24-h duration of action. J Pharmacol Exp Ther 2006;317:762-70
   PubMed Web of Science ®Google Scholar
• Naline E, Trifilieff A, Fairhurst RA, Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007;29:575-81
   PubMed Web of Science ®Google Scholar
• Beier J, Chanez P, Martinot J-B, Safety, tolerability and efficacy of indacaterol, a novel once-daily beta2 agonist, in patients with COPD: A 28-day randomized, placebo controlled clinical trial. Pulm Pharmacol Ther 2007;20:740-9
   PubMed Web of Science ®Google Scholar
• Rennard S, Bantje T, Centanni S, A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-44
   PubMed Web of Science ®Google Scholar
• Bauwens O, Ninane V, Van de Paele R, 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009;25:463-70
   PubMed Web of Science ®Google Scholar
• Beier J, Beeh KM, Brookman L, Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22:492-6
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pococi SJ, Magnussen H, Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71
   PubMed Web of Science ®Google Scholar
• Feldman G, Siler T, Prasad N, Efficacy and safety of indacaterol 150 mcg once daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med 2010: published online 8 March 2010, doi:10.1186/1471-2466-10-11
   PubMedGoogle Scholar
• Dahl R, Fan Chung K, Buhl R, Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax 2010;66:473-9
   Google Scholar
• Donohue JF, Fogarty C, Lotvall J, Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010: published online 12 May 2010, doi:10.1164/rccm.200910-1500OC
   PubMedGoogle Scholar
• Kornmann O, Luthra A, Owen R, Once-daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive pulmonary disease: a 26-week placebo-controlled study Meeting abstracts. Chest 2009;136:152S
   Google Scholar
• Vogelmeier C, Ramos-Barbon D, Jack D, Once-daily indacaterol provides effective 24-hour bronchodilation in COPD: a double-blind comparison with tiotropium Meeting abstracts. Chest 2009;136:4S-5S
   Google Scholar
• Cazzola M, Bettoncelli G, Sessa E, Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010: published online 4 February 2010, doi:10.1159/000281880
   PubMedGoogle Scholar
• Au D, Udris EM, Fan VS, Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123:1964-9
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Wang D, Petrie MC, Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010, doi:10.109/eurjhf/hfq040
   Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008;300:1439-50
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulm Dis 2008;3:1-7
   PubMedGoogle Scholar
• Lee TA, Pickard S, Au DH, Risk of death associated with medications for recently prescribed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90
   PubMed Web of Science ®Google Scholar
• Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009;29:891-905
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Leimer I, Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-59
   PubMed Web of Science ®Google Scholar
• Soriano JB, Davis KJ, Coleman B, The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003;124:474-81
   PubMed Web of Science ®Google Scholar
• Bleecker ER. Similarities and differences in asthma and COPD. The Dutch Hypothesis. Chest 2004;126:93S-5S
   PubMedGoogle Scholar
• Nelson HS, Weiss ST, Bleecker ER, The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007;356:2211-12
   PubMed Web of Science ®Google Scholar
• Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD. COPD 2009;6:404-15
   PubMedGoogle Scholar
• Aaron SD, Vandemheen KL, Fergusson D, Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007;146:545-55
   PubMed Web of Science ®Google Scholar